-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Private Equity Firms Among Everest Medicines Limited's (HKG:1952) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Private Equity Firms Among Everest Medicines Limited's (HKG:1952) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
If you want to know who really controls Everest Medicines Limited (HKG:1952), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are private equity firms with 52% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
As a result, private equity firms as a group endured the highest losses last week after market cap fell by HK$429m.
Let's take a closer look to see what the different types of shareholders can tell us about Everest Medicines.
View our latest analysis for Everest Medicines
SEHK:1952 Ownership Breakdown September 7th 2022What Does The Institutional Ownership Tell Us About Everest Medicines?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
As you can see, institutional investors have a fair amount of stake in Everest Medicines. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Everest Medicines' historic earnings and revenue below, but keep in mind there's always more to the story.
SEHK:1952 Earnings and Revenue Growth September 7th 2022Our data indicates that hedge funds own 5.8% of Everest Medicines. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. CBC Group is currently the largest shareholder, with 43% of shares outstanding. For context, the second largest shareholder holds about 8.9% of the shares outstanding, followed by an ownership of 5.8% by the third-largest shareholder.
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
Insider Ownership Of Everest Medicines
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our most recent data indicates that insiders own some shares in Everest Medicines Limited. In their own names, insiders own HK$49m worth of stock in the HK$3.1b company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
General Public Ownership
The general public-- including retail investors -- own 29% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
With an ownership of 52%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For example, we've discovered 3 warning signs for Everest Medicines (1 is concerning!) that you should be aware of before investing here.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道谁真正控制了珠峰医药有限公司(HKG:1952),那么你就得看看它的股票登记簿的构成。而在这块蛋糕上分得最大一块蛋糕的是拥有52%股权的私募股权公司。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
其结果是,在市值缩水4.29亿港元后,私人股本公司作为一个整体上周遭受了最大的损失。
让我们仔细看看不同类型的股东能告诉我们关于珠峰医药公司的什么。
查看我们对珠峰药品的最新分析
联交所:1952年9月7日所有权分类关于珠峰医药,机构所有权告诉了我们什么?
机构通常在向自己的投资者报告时,以基准来衡量自己,因此一旦一只股票被纳入主要指数,它们往往会对这只股票变得更加热情。我们预计,大多数公司都会有一些机构登记在册,特别是在它们正在增长的情况下。
正如你所看到的,机构投资者在珠峰医药公司拥有相当数量的股份。这意味着为这些机构工作的分析师已经看过了这只股票,他们喜欢它。但就像其他人一样,他们也可能错了。当多家机构持有一只股票时,它们总是面临“拥挤交易”的风险。当这样的交易出错时,多方可能会竞相快速抛售股票。在一家没有增长历史的公司,这一风险更高。你可以在下面看到珠峰医药公司的历史收益和收入,但请记住,故事中总是有更多的东西。
联交所:1952年盈利及收入增长2022年9月7日我们的数据显示,对冲基金拥有珠峰医药公司5.8%的股份。这一点值得注意,因为对冲基金往往是相当活跃的投资者,他们可能会试图影响管理层。许多人希望在短期或中期看到价值创造(以及更高的股价)。CBC集团目前是最大股东,持有43%的流通股。作为参考,第二大股东持有约8.9%的流通股,第三大股东持有5.8%的股份。
为了让我们的研究更有趣,我们发现,前两名股东拥有公司的多数股权,这意味着他们足够强大,可以影响公司的决策。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。相当多的分析师追踪这只股票,所以你可以很容易地研究预测增长。
珠峰医药的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
我们的最新数据显示,内部人士持有珠峰医药有限公司的部分股份。内部人士以个人名义持有这家市值31亿港元的公司价值4900万港元的股票。有人会说,这表明股东和董事会之间的利益一致。但或许值得一查的是,这些内部人士是否一直在抛售。
一般公有制
包括散户投资者在内的普通公众持有该公司29%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私募股权所有权
私募股权公司拥有52%的股权,能够在塑造专注于价值创造的公司战略方面发挥作用。有时我们会看到私募股权投资长期存在,但总的来说,它们的投资期限较短,而且--顾名思义--不会对上市公司进行太多投资。一段时间后,他们可能会考虑出售并将资本重新配置到其他地方。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。例如,我们发现珠峰医药的3个警告标志(1是关于!)在这里投资之前你应该意识到这一点。
但最终这就是未来,而不是过去,这将决定这家企业的所有者将做得多好。因此,我们认为,看看这份免费报告是明智的,它显示了分析师是否预测到了更光明的未来。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗?保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧